urovestВестник урологииUrology Herald2308-6424Rostov State Medical University10.21886/2308-6424-2024-12-4-155-158urovest-914Research ArticleОБЗОРЫ ПУБЛИКАЦИЙ – ТЕКУЩЕЕ МНЕНИЕCURRENT STATE-OF-THE-ARTРак мочевого пузыря: вопросы, требующие дополнительного изученияBladder cancer: issues requiring further researchhttps://orcid.org/0009-0007-6904-7682РожковИ. А.RozhkovI. A.

Рожков Иван Алексеевич.

Москва

Ivan A. Rozhkov.

Moscow

ivanrozhkoff@yandex.ruhttps://orcid.org/0000-0003-3947-1267БулычкинП. В.BulychkinP. V.

Булычкин Пётр Владиславович — канд. мед. наук.

Москва

Pyotr V. Bulychkin — Cand.Sc.(Med).

Moscow

petrbulychkin@gmail.comНациональный медицинский исследовательский центр онкологии им. Н.Н. БлохинаРоссияBlokhin National Medical Research Centre for OncologyRussian Federation202405092024124155158Copyright © Рожков И.А., Булычкин П.В., 20242024Рожков И.А., Булычкин П.В.Rozhkov I.A., Bulychkin P.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.urovest.ru/jour/article/view/914

В статье обсуждаются вопросы, касающиеся лечения больных с местнораспространённым раком мочевого пузыря.

The article discusses issues related to the treatment of patients diagnosed with locally advanced bladder cancer.

рак мочевого пузырятримодальная терапияхимиолучевая терапияцистэктомияbladder cancertrimodal therapychemoradiotherapycystectomyReferencesDing H, Fan N, Ning Z, Ma D. Trimodal Therapy vs. Radical Cystectomy for Muscle-Invasive Bladder Cancer: A Meta-Analysis. Front Oncol. 2020;10:564779. DOI: 10.3389/fonc.2020.564779Ding H, Fan N, Ning Z, Ma D. Trimodal Therapy vs. Radical Cystectomy for Muscle-Invasive Bladder Cancer: A Meta-Analysis. Front Oncol. 2020;10:564779. DOI: 10.3389/fonc.2020.564779Dracham CB, Kumar N, Kumar S, Elangovan A, Yadav BS, Mavuduru RS, Lal A, Gupta PK, Kapoor R. A phase II study of neoadjuvant chemotherapy followed by organ preservation in patients with muscle-invasive bladder cancer. Asian J Urol. 2022;9(3):318-328. DOI: 10.1016/j.ajur.2021.06.006Dracham CB, Kumar N, Kumar S, Elangovan A, Yadav BS, Mavuduru RS, Lal A, Gupta PK, Kapoor R. A phase II study of neoadjuvant chemotherapy followed by organ preservation in patients with muscle-invasive bladder cancer. Asian J Urol. 2022;9(3):318-328. DOI: 10.1016/j.ajur.2021.06.006Swinton M, Mariam NBG, Tan JL, Murphy K, Elumalai T, Soni M, Ferrera A, Richardson C, Walshaw R, Mistry H, Ramani V, Song Y, Birtle A, Henry A, Chan J, Hoskin P, Choudhury A. Bladder-Sparing Treatment With Radical Dose Radiotherapy Is an Effective Alternative to Radical Cystectomy in Patients With Clinically Node-Positive Nonmetastatic Bladder Cancer. J Clin Oncol. 2023;41(27):4406-4415. DOI: 10.1200/JCO.23.00725Swinton M, Mariam NBG, Tan JL, Murphy K, Elumalai T, Soni M, Ferrera A, Richardson C, Walshaw R, Mistry H, Ramani V, Song Y, Birtle A, Henry A, Chan J, Hoskin P, Choudhury A. Bladder-Sparing Treatment With Radical Dose Radiotherapy Is an Effective Alternative to Radical Cystectomy in Patients With Clinically Node-Positive Nonmetastatic Bladder Cancer. J Clin Oncol. 2023;41(27):4406-4415. DOI: 10.1200/JCO.23.00725Tan MP, Harris V, Warren-Oseni K, McDonald F, McNair H, Taylor H, Hansen V, Sharabiani M, Thomas K, Jones K, Dearnaley D, Hafeez S, Huddart RA. The Intensity-Modulated Pelvic Node and Bladder Radiotherapy (IMPART) Trial: A Phase II Single-Centre Prospective Study. Clin Oncol (R Coll Radiol). 2020;32(2):93-100. DOI: 10.1016/j.clon.2019.07.017Tan MP, Harris V, Warren-Oseni K, McDonald F, McNair H, Taylor H, Hansen V, Sharabiani M, Thomas K, Jones K, Dearnaley D, Hafeez S, Huddart RA. The Intensity-Modulated Pelvic Node and Bladder Radiotherapy (IMPART) Trial: A Phase II Single-Centre Prospective Study. Clin Oncol (R Coll Radiol). 2020;32(2):93-100. DOI: 10.1016/j.clon.2019.07.017Powles T, Park SH, Voog E, Caserta C, Valderrama BP, Gurney H, Kalofonos H, Radulović S, Demey W, Ullén A, Loriot Y, Sridhar SS, Tsuchiya N, Kopyltsov E, Sternberg CN, Bellmunt J, Aragon-Ching JB, Petrylak DP, Laliberte R, Wang J, Huang B, Davis C, Fowst C, Costa N, Blake-Haskins JA, di Pietro A, Grivas P. Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma. N Engl J Med. 2020;383(13):1218-1230. DOI: 10.1056/NEJMoa2002788Powles T, Park SH, Voog E, Caserta C, Valderrama BP, Gurney H, Kalofonos H, Radulović S, Demey W, Ullén A, Loriot Y, Sridhar SS, Tsuchiya N, Kopyltsov E, Sternberg CN, Bellmunt J, Aragon-Ching JB, Petrylak DP, Laliberte R, Wang J, Huang B, Davis C, Fowst C, Costa N, Blake-Haskins JA, di Pietro A, Grivas P. Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma. N Engl J Med. 2020;383(13):1218-1230. DOI: 10.1056/NEJMoa2002788Joshi M, Tuanquin L, Zhu J, Walter V, Schell T, Kaag M, Kilari D, Liao J, Holder SL, Emamekhoo H, Sankin A, Merrill S, Zheng H, Warrick J, Hauke R, Gartrel B, Stein M, Drabick J, Degraff DJ, Zakharia Y. Concurrent durvalumab and radiation therapy (DUART) followed by adjuvant durvalumab in patients with localized urothelial cancer of bladder: results from phase II study, BTCRC-GU15-023. J Immunother Cancer. 2023;11(2):e006551. DOI: 10.1136/jitc-2022-006551Joshi M, Tuanquin L, Zhu J, Walter V, Schell T, Kaag M, Kilari D, Liao J, Holder SL, Emamekhoo H, Sankin A, Merrill S, Zheng H, Warrick J, Hauke R, Gartrel B, Stein M, Drabick J, Degraff DJ, Zakharia Y. Concurrent durvalumab and radiation therapy (DUART) followed by adjuvant durvalumab in patients with localized urothelial cancer of bladder: results from phase II study, BTCRC-GU15-023. J Immunother Cancer. 2023;11(2):e006551. DOI: 10.1136/jitc-2022-006551

The authors declare that there are no conflicts of interest present.